IP Verse

Methods For Treating Hepcidin-Mediated Disorders

PatentPatent Analysis

EP3329018

ASTRAZENECA PHARMACEUTICALS
Application Number
EP16833574A
Filing Date
Jul 28, 2016
Status
Revoked
Nov 23, 2024
Grant Date
Mar 31, 2021
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP4175619B1
EP4175620B1
EP4197528B1

Bibliography

The patent EP3329018B1 was granted to Astrazeneca Pharmaceuticals on Mar 31, 2021 following the initial filing on Jul 28, 2016 under the application number EP16833574A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANDec 24, 2021ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents